Lee Sang-Min, Hay Debbie L, Pioszak Augen A
From the Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104 and.
the School of Biological Sciences and Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland 1142, New Zealand.
J Biol Chem. 2016 Apr 15;291(16):8686-700. doi: 10.1074/jbc.M115.713628. Epub 2016 Feb 19.
Receptor activity-modifying proteins (RAMP1-3) determine the selectivity of the class B G protein-coupled calcitonin receptor (CTR) and the CTR-like receptor (CLR) for calcitonin (CT), amylin (Amy), calcitonin gene-related peptide (CGRP), and adrenomedullin (AM) peptides. RAMP1/2 alter CLR selectivity for CGRP/AM in part by RAMP1 Trp-84 or RAMP2 Glu-101 contacting the distinct CGRP/AM C-terminal residues. It is unclear whether RAMPs use a similar mechanism to modulate CTR affinity for CT and Amy, analogs of which are therapeutics for bone disorders and diabetes, respectively. Here, we reproduced the peptide selectivity of intact CTR, AMY1 (CTR·RAMP1), and AMY2 (CTR·RAMP2) receptors using purified CTR extracellular domain (ECD) and tethered RAMP1- and RAMP2-CTR ECD fusion proteins and antagonist peptides. All three proteins bound salmon calcitonin (sCT). Tethering RAMPs to CTR enhanced binding of rAmy, CGRP, and the AMY antagonist AC413. Peptide alanine-scanning mutagenesis and modeling of receptor-bound sCT and AC413 supported a shared non-helical CGRP-like conformation for their TN(T/V)G motif prior to the C terminus. After this motif, the peptides diverged; the sCT C-terminal Pro was crucial for receptor binding, whereas the AC413/rAmy C-terminal Tyr had little or no influence on binding. Accordingly, mutant RAMP1 W84A- and RAMP2 E101A-CTR ECD retained AC413/rAmy binding. ECD binding and cell-based signaling assays with antagonist sCT/AC413/rAmy variants with C-terminal residue swaps indicated that the C-terminal sCT/rAmy residue identity affects affinity more than selectivity. rAmy(8-37) Y37P exhibited enhanced antagonism of AMY1 while retaining selectivity. These results reveal unexpected differences in how RAMPs determine CTR and CLR peptide selectivity and support the hypothesis that RAMPs allosterically modulate CTR peptide affinity.
受体活性调节蛋白(RAMP1 - 3)决定了B类G蛋白偶联降钙素受体(CTR)和降钙素受体样受体(CLR)对降钙素(CT)、胰淀素(Amy)、降钙素基因相关肽(CGRP)和肾上腺髓质素(AM)肽的选择性。RAMP1/2部分通过RAMP1的色氨酸84或RAMP2的谷氨酸101与CGRP/AM不同的C末端残基接触来改变CLR对CGRP/AM的选择性。尚不清楚RAMP是否使用类似机制来调节CTR对CT和Amy的亲和力,CT和Amy的类似物分别是治疗骨疾病和糖尿病的药物。在这里,我们使用纯化的CTR细胞外结构域(ECD)以及与RAMP1和RAMP2相连的CTR ECD融合蛋白和拮抗剂肽,重现了完整的CTR、AMY1(CTR·RAMP1)和AMY2(CTR·RAMP2)受体的肽选择性。这三种蛋白都能结合鲑鱼降钙素(sCT)。将RAMP与CTR相连可增强rAmy、CGRP和AMY拮抗剂AC413的结合。肽丙氨酸扫描诱变以及受体结合的sCT和AC413的建模支持了它们在C末端之前的TN(T/V)G基序具有共同的非螺旋CGRP样构象。在此基序之后,这些肽出现分歧;sCT的C末端脯氨酸对受体结合至关重要,而AC413/rAmy的C末端酪氨酸对结合几乎没有影响。因此,突变型RAMP1 W84A - 和RAMP2 E101A - CTR ECD保留了AC413/rAmy的结合。使用具有C末端残基交换的拮抗剂sCT/AC413/rAmy变体进行的ECD结合和基于细胞的信号传导分析表明,C末端sCT/rAmy残基的同一性对亲和力的影响大于对选择性的影响。rAmy(8 - 37) Y37P在保留选择性的同时,对AMY1表现出增强的拮抗作用。这些结果揭示了RAMP决定CTR和CLR肽选择性的方式存在意想不到的差异,并支持RAMP变构调节CTR肽亲和力的假设。